Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 10:40AM ET
13.65
Dollar change
-0.06
Percentage change
-0.41
%
IndexRUT P/E- EPS (ttm)-7.54 Insider Own18.31% Shs Outstand59.97M Perf Week1.22%
Market Cap818.84M Forward P/E- EPS next Y-2.48 Insider Trans0.94% Shs Float48.99M Perf Month2.82%
Income-232.03M PEG- EPS next Q-0.37 Inst Own60.30% Short Float22.94% Perf Quarter-20.52%
Sales12.68M P/S64.58 EPS this Y33.43% Inst Trans-0.12% Short Ratio11.20 Perf Half Y1.29%
Book/sh4.78 P/B2.85 EPS next Y30.67% ROA-126.15% Short Interest11.24M Perf Year77.79%
Cash/sh5.16 P/C2.64 EPS next 5Y- ROE-154.98% 52W Range6.13 - 30.96 Perf YTD27.61%
Dividend Est.- P/FCF- EPS past 5Y-48.48% ROI-80.91% 52W High-55.89% Beta1.79
Dividend TTM- Quick Ratio10.18 Sales past 5Y0.00% Gross Margin93.35% 52W Low122.74% ATR (14)0.80
Dividend Ex-Date- Current Ratio10.18 EPS Y/Y TTM-203.81% Oper. Margin-1871.47% RSI (14)52.09 Volatility6.15% 6.11%
Employees55 Debt/Eq0.01 Sales Y/Y TTM436.51% Profit Margin-1829.44% Recom1.00 Target Price31.40
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-616.75% Payout- Rel Volume0.16 Prev Close13.71
Sales Surprise-63.25% EPS Surprise-269.12% Sales Q/Q-56.47% EarningsMay 14 BMO Avg Volume1.00M Price13.65
SMA208.20% SMA50-2.03% SMA200-6.32% Trades Volume35,936 Change-0.41%
Date Action Analyst Rating Change Price Target Change
May-31-24Initiated Piper Sandler Overweight $27
Apr-30-24Initiated JP Morgan Overweight $24
Apr-15-24Initiated Guggenheim Buy $35
Jan-29-24Initiated Leerink Partners Outperform $30
Dec-19-23Initiated Wedbush Outperform $12
Oct-29-21Initiated Cantor Fitzgerald Overweight $35
Jul-09-24 07:00AM
Jun-27-24 08:00AM
May-22-24 02:05PM
May-21-24 07:01PM
May-20-24 11:14AM
08:00AM Loading…
08:00AM
May-17-24 08:51AM
08:00AM
May-14-24 01:54PM
09:10AM
08:00AM
May-08-24 08:00AM
May-02-24 08:00AM
Apr-30-24 07:29AM
Apr-26-24 10:00AM
08:26AM Loading…
Apr-25-24 08:26AM
Apr-05-24 08:00AM
Mar-28-24 11:53PM
04:02PM
Mar-26-24 08:00AM
08:00AM
Mar-18-24 05:44AM
Mar-07-24 08:00AM
Mar-04-24 07:00AM
Mar-01-24 08:00AM
Feb-20-24 08:15AM
08:00AM
Feb-16-24 04:05PM
Feb-13-24 10:38PM
04:05PM
08:34AM Loading…
Feb-07-24 08:34AM
Feb-06-24 09:20AM
08:00AM
Feb-05-24 08:00AM
Jan-08-24 07:00AM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
Jan-02-24 08:00AM
Dec-26-23 08:30AM
08:30AM
Nov-10-23 08:00AM
Nov-09-23 08:00AM
Nov-08-23 08:00AM
Oct-23-23 02:50AM
Oct-19-23 08:00AM
Oct-04-23 11:00PM
Oct-03-23 08:00AM
Aug-17-23 08:19PM
Aug-09-23 08:00AM
Jun-30-23 09:51AM
Jun-29-23 09:00AM
Jun-02-23 07:55AM
May-23-23 04:05PM
May-09-23 08:50AM
May-05-23 08:00AM
Apr-20-23 08:50AM
Mar-16-23 08:00AM
Mar-13-23 07:32AM
Mar-09-23 08:45AM
Feb-08-23 08:00AM
Jan-31-23 06:52AM
Jan-06-23 04:05PM
02:46PM
10:35AM
08:00AM
Nov-14-22 08:00AM
Nov-09-22 12:00PM
Oct-04-22 06:08AM
Aug-24-22 06:59AM
Aug-23-22 09:00AM
Aug-05-22 08:00AM
Jul-06-22 09:28AM
08:00AM
Jun-09-22 08:00AM
Jun-02-22 08:00AM
May-26-22 08:07AM
May-23-22 08:00AM
May-19-22 03:27PM
11:31AM
08:00AM
May-12-22 08:00AM
Mar-28-22 08:00AM
Mar-17-22 06:40AM
Mar-14-22 12:30PM
Mar-11-22 10:48AM
08:00AM
Feb-08-22 03:00PM
10:22AM
08:00AM
Jan-11-22 09:56AM
06:46AM
Jan-10-22 04:15PM
Dec-17-21 07:11AM
Dec-07-21 07:00AM
Dec-01-21 01:12PM
07:00AM
Nov-29-21 07:00AM
Nov-15-21 05:00PM
Nov-09-21 04:05PM
Oct-20-21 08:00AM
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOMay 21 '24Buy13.7820,434281,548419,636May 21 04:13 PM
BIENAIME JEAN JACQUESDirectorMay 21 '24Buy13.572,00027,1409,615May 22 04:49 PM
SIEGALL CLAY BPresident and CEOMay 20 '24Buy13.9179,5661,106,524399,202May 21 04:13 PM
SIEGALL CLAY BPresident and CEOOct 02 '23Buy5.91169,204999,996319,636Oct 04 05:35 PM
Turner BruceChief Strategy OfficerOct 02 '23Buy5.9142,300249,99342,300Oct 04 05:32 PM
Last Close
Jul 19 10:40AM ET
83.40
Dollar change
+0.06
Percentage change
0.07
%
BMRN Biomarin Pharmaceutical Inc. daily Stock Chart
Index- P/E78.05 EPS (ttm)1.07 Insider Own1.90% Shs Outstand188.60M Perf Week-1.90%
Market Cap15.84B Forward P/E29.51 EPS next Y2.83 Insider Trans-6.04% Shs Float186.28M Perf Month-0.89%
Income205.46M PEG1.82 EPS next Q0.36 Inst Own99.48% Short Float4.52% Perf Quarter-7.40%
Sales2.48B P/S6.39 EPS this Y104.54% Inst Trans2.04% Short Ratio3.24 Perf Half Y-9.87%
Book/sh26.74 P/B3.12 EPS next Y58.84% ROA3.09% Short Interest8.42M Perf Year-4.22%
Cash/sh5.51 P/C15.13 EPS next 5Y43.00% ROE4.22% 52W Range73.68 - 99.56 Perf YTD-13.50%
Dividend Est.- P/FCF87.10 EPS past 5Y- ROI3.63% 52W High-16.23% Beta0.32
Dividend TTM- Quick Ratio1.70 Sales past 5Y10.23% Gross Margin76.81% 52W Low13.20% ATR (14)1.89
Dividend Ex-Date- Current Ratio2.74 EPS Y/Y TTM183.46% Oper. Margin8.60% RSI (14)51.10 Volatility2.32% 2.32%
Employees3401 Debt/Eq0.22 Sales Y/Y TTM16.45% Profit Margin8.30% Recom1.66 Target Price109.39
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q75.38% Payout0.00% Rel Volume0.21 Prev Close83.34
Sales Surprise-0.46% EPS Surprise47.53% Sales Q/Q9.61% EarningsApr 24 AMC Avg Volume2.60M Price83.40
SMA20-0.23% SMA502.70% SMA200-3.92% Trades Volume119,443 Change0.07%
Date Action Analyst Rating Change Price Target Change
May-17-24Downgrade Robert W. Baird Outperform → Neutral $104 → $72
May-14-24Initiated Evercore ISI Outperform $113
Nov-15-23Initiated Wells Fargo Overweight $100
Oct-23-23Upgrade Bernstein Underperform → Mkt Perform $82
Sep-28-23Initiated Raymond James Mkt Perform
Sep-18-23Initiated UBS Buy $120
Jul-27-23Initiated Scotiabank Sector Perform $95
Jul-05-23Upgrade BMO Capital Markets Market Perform → Outperform $102
Jun-14-23Resumed Credit Suisse Outperform $120
Mar-21-23Initiated Bernstein Underperform $81
Jul-15-24 08:41AM
Jul-01-24 09:20AM
Jun-20-24 03:18AM
Jun-17-24 08:30AM
Jun-11-24 10:57AM
06:09PM Loading…
Jun-07-24 06:09PM
09:00AM
Jun-05-24 06:14AM
Jun-04-24 08:00AM
May-25-24 11:10PM
May-24-24 11:31AM
May-18-24 05:06AM
May-15-24 07:00AM
May-13-24 04:14PM
May-09-24 06:15AM
08:00AM Loading…
May-08-24 08:00AM
May-06-24 07:00PM
04:47PM
May-04-24 04:00PM
May-03-24 02:31PM
Apr-29-24 02:26PM
Apr-27-24 05:06AM
01:07AM
Apr-26-24 08:49AM
06:53AM
Apr-25-24 01:30PM
11:48AM
11:44AM
10:47AM
10:31AM
07:39AM Loading…
07:39AM
06:46AM
03:19AM
Apr-24-24 06:30PM
05:33PM
05:15PM
04:23PM
04:14PM
04:03PM
Apr-23-24 11:36AM
Apr-22-24 04:26PM
09:16AM
Apr-17-24 10:01AM
Apr-12-24 07:00PM
Apr-10-24 08:00AM
Apr-01-24 07:01PM
Mar-17-24 08:50AM
Mar-16-24 05:06AM
Mar-12-24 08:30AM
Mar-11-24 10:00AM
Mar-08-24 01:31AM
Mar-07-24 08:30AM
Mar-01-24 09:00AM
Feb-27-24 12:03AM
Feb-26-24 02:36PM
02:12PM
Feb-23-24 04:29PM
12:33PM
11:34AM
07:21AM
05:43AM
04:25AM
Feb-22-24 06:00PM
05:15PM
04:42PM
04:23PM
04:03PM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-13-24 01:10PM
Feb-08-24 04:10PM
08:00AM
Feb-07-24 05:21AM
Feb-06-24 08:30AM
Jan-24-24 11:21AM
Jan-23-24 08:00AM
Jan-20-24 05:06AM
Jan-15-24 09:45AM
Jan-10-24 06:16PM
Jan-03-24 08:00AM
Dec-21-23 06:14AM
Dec-20-23 05:08PM
04:05PM
Dec-14-23 07:05PM
Dec-05-23 11:01AM
Dec-02-23 05:06AM
Dec-01-23 11:31AM
Nov-29-23 09:13PM
06:30AM
Nov-28-23 11:09AM
08:30AM
Nov-16-23 08:47AM
Nov-10-23 12:58AM
Nov-09-23 04:43PM
03:49AM
Nov-08-23 05:19AM
Nov-07-23 07:09PM
05:07PM
02:24PM
Nov-06-23 07:20PM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MEIER RICHARD ADirectorJun 03 '24Option Exercise63.106,600416,460126,227Jun 04 07:28 PM
HERON ELAINE JDirectorJun 03 '24Option Exercise63.105,047318,466101,888Jun 04 07:29 PM
Mueller BrianEVP, Chief Financial OfficerMay 30 '24Option Exercise63.105,000315,50077,159May 31 06:28 PM
Mueller BrianEVP, Chief Financial OfficerMay 30 '24Sale75.195,000375,95072,159May 31 06:28 PM
Davis George EricEVP, Chief Legal OfficerMay 28 '24Option Exercise63.1040,8502,577,63597,007May 30 06:18 PM
Davis George EricEVP, Chief Legal OfficerMay 28 '24Sale74.5140,8503,043,80256,157May 30 06:18 PM
BIENAIME JEAN JACQUESDirectorMay 10 '24Option Exercise63.1020,0001,262,000494,994May 13 03:57 PM
BIENAIME JEAN JACQUESDirectorMay 10 '24Sale81.1420,0001,622,800474,994May 13 03:57 PM
BIENAIME JEAN JACQUESDirectorMay 09 '24Option Exercise63.1020,0001,262,000494,994May 13 03:57 PM
BIENAIME JEAN JACQUESDirectorMay 09 '24Sale81.6220,0001,632,400474,994May 13 03:57 PM
Davis George EricEVP, Chief Legal OfficerMay 02 '24Option Exercise63.101,850116,73558,007May 06 04:45 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 02 '24Sale82.915,000414,55066,767May 06 04:40 PM
Davis George EricEVP, Chief Legal OfficerMay 02 '24Sale85.011,850157,26856,157May 06 04:45 PM
BIENAIME JEAN JACQUESDirectorApr 12 '24Option Exercise63.1020,0001,262,000494,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 12 '24Sale91.2620,0001,825,200474,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 11 '24Option Exercise63.1020,0001,262,000494,994Apr 15 04:21 PM
BIENAIME JEAN JACQUESDirectorApr 11 '24Sale90.9920,0001,819,800474,994Apr 15 04:21 PM
Burkhart ErinGVP, Chief Accounting OfficerApr 10 '24Sale90.002,286205,74016,156Apr 12 03:07 PM
Davis George EricEVP, Chief Legal OfficerMar 28 '24Sale88.3424,6022,173,34155,856Apr 01 04:54 PM
Slamon DennisDirectorMar 18 '24Option Exercise79.7010,000797,00040,809Mar 20 05:13 PM
BIENAIME JEAN JACQUESDirectorMar 06 '24Sale86.711,00086,713560,203Mar 07 05:35 PM
FUCHS HENRY JPresident, Worldwide R&DMar 05 '24Sale85.1835,3413,010,396212,117Mar 07 06:54 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 05 '24Sale87.074,000348,28094,047Mar 07 05:32 PM
BIENAIME JEAN JACQUESDirectorMar 05 '24Sale85.511,00085,510561,203Mar 07 05:35 PM
BIENAIME JEAN JACQUESDirectorFeb 27 '24Sale90.351,00090,350562,203Feb 29 05:05 PM
BIENAIME JEAN JACQUESDirectorFeb 09 '24Option Exercise63.1015,000946,500434,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 09 '24Sale88.2815,0001,324,200419,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 08 '24Option Exercise63.1015,000946,500434,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorFeb 08 '24Sale89.7715,0001,346,550419,602Feb 12 05:20 PM
BIENAIME JEAN JACQUESDirectorJan 10 '24Option Exercise63.1010,000631,000435,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 10 '24Sale96.3810,000963,800425,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 09 '24Option Exercise63.1010,000631,000435,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorJan 09 '24Sale98.1910,000981,900425,162Jan 11 02:40 PM
BIENAIME JEAN JACQUESDirectorDec 21 '23Option Exercise63.1010,000631,000435,112Dec 22 05:14 PM
BIENAIME JEAN JACQUESDirectorDec 21 '23Sale93.9910,000939,900425,112Dec 22 05:14 PM
Davis George EricEVP, Chief Legal OfficerDec 13 '23Sale95.3013,7641,311,70955,710Dec 14 06:18 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerAug 16 '23Sale90.005,000450,00060,804Aug 17 03:57 PM
FUCHS HENRY JPresident, Worldwide R&DAug 10 '23Sale90.4312,0001,085,111176,187Aug 11 01:59 PM
Guyer Charles GregEVP, Chief Technical OfficerAug 09 '23Sale93.305,360500,10940,041Aug 10 04:47 PM
Davis George EricEVP, Chief Legal OfficerAug 08 '23Sale89.4211,000983,66269,474Aug 09 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 08 '23Sale88.296,000529,740422,732Aug 09 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 07 '23Sale88.104,000352,400428,732Aug 09 07:05 PM